Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $18,760.00 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 500 shares of the firm’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $37.52, for a total value of $18,760.00. Following the transaction, the insider owned 54,645 shares in the company, valued at approximately $2,050,280.40. This represents a 0.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Gheuens also recently made the following trade(s):

• On Wednesday, October 21st, Sarah Gheuens sold 1,489 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $37.53, for a total value of $55,882.17.
• On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $30.48, for a total value of $914,400.00.

Agios Pharmaceuticals Stock Down 0.5%

NASDAQ:AGIO traded down $0.19 during mid-day trading on Friday, reaching $37.00. The company’s stock had a trading volume of 920,048 shares, compared to its average volume of 1,059,158. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00. The stock has a fifty day moving average of $33.34 and a 200-day moving average of $32.76. The firm has a market capitalization of $2.21 billion, a PE ratio of -5.28 and a beta of 0.63.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The business had revenue of $44.75 million for the quarter, compared to analysts’ expectations of $26.39 million. On average, analysts expect that Agios Pharmaceuticals, Inc. will post -5.83 earnings per share for the current year.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. BlackRock Inc. purchased a new stake in Agios Pharmaceuticals during the 2nd quarter valued at about $239,582,000. Assenagon Asset Management S.A. increased its holdings in shares of Agios Pharmaceuticals by 1,714.6% in the third quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after purchasing an additional 1,782,457 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at about $47,800,000. Dimensional Fund Advisors LP raised its stake in shares of Agios Pharmaceuticals by 14.7% in the first quarter. Dimensional Fund Advisors LP now owns 1,151,614 shares of the biopharmaceutical company’s stock worth $38,940,000 after purchasing an additional 147,273 shares during the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new position in shares of Agios Pharmaceuticals in the second quarter worth about $24,828,000.

Analysts Set New Price Targets

AGIO has been the topic of several analyst reports. HC Wainwright lifted their price target on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Royal Bank Of Canada lifted their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Bank of America boosted their target price on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. JPMorgan Chase & Co. upped their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Finally, Truist Financial decreased their price target on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating for the company in a report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Agios Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $41.50.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.